Tyndall National Institute, MCCI’s host institute, has been named a research partner in two of the six projects awarded funding under Call 7 of the Disruptive Technologies Innovation Fund (DTIF). The €36.9 million investment, announced by Minister Peter Burke and Minister James Lawless, supports transformative innovation across healthcare, ICT, and advanced manufacturing.
Within this announcement, MCCI will contribute its microelectronics expertise to SensABLATE, a €11.1 million project focused on developing advanced, non-invasive therapeutic technologies. Led by Endowave Ltd, the consortium — which also includes Quadrant Scientific Ltd, Atlantic Technological University, and Tyndall — aims to create a smart ablation catheter capable of precisely removing or treating unwanted tissue, such as tumours or cardiac lesions, without major surgery.
John Morrissey, Executive Director of MCCI and Tyndall’s project lead for SensABLATE, said:
“This DTIF partnership will combine four cutting-edge technologies into a single system that enhances surgical treatments and outcomes. MCCI’s expertise in magnetic sensor microchips is central to enabling this innovation.”
MCCI’s participation in SensABLATE underscores its leadership in microelectronics and sensing research, driving innovation in MedTech and contributing to Ireland’s growing reputation in disruptive technology development.
For more information on DTIF Call 7, visit: gov.ie/disruptivetechfund